3SBio Inc (SSRX)

[surf1944]

7:05AM 3SBIO and Isotechnika Pharma announce strategic partnership to develop and commercialize Voclosporin in China (SSRX) 12.84 : Co and Isotechnika Pharma Inc. announce the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases. Under the terms of the agreement, Isotechnika will grant co exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, excluding certain items. Co will be responsible for the clinical development, registration and commercialization of voclosporin in China. Isotechnika will provide, under separate agreement, commercial supply to 3SBio on a cost-plus basis. Isotechnika will receive an upfront non-refundable licensing payment of $1.5 million. Isotechnika will also receive ongoing royalties based on sales of voclosporin by co.